You are here

We are pleased to announce the appointment of Dr. Mark Moore as Executive Director for the International Mouse Phenotyping Consortium. Mark brings extensive experience in mouse genetics and mouse phenotyping from industry and the IMPC Steering Committee are delighted to have him on board. Mark worked at Genentech in the early 90's where he used gene knockouts as drug discovery and validation tools. His work included the potential targets Her2 and Vegf, and his work helped in the development of the blockbuster cancer drugs Herceptin and Avastin. Mark subsequently founded Deltagen whose mission was to perform high throughput gene targeting and phenotyping to discover novel drug targets; under his direction, the company reached an output of over 250 lines per year. For the past 6 years, he has worked as a Senior Consultant for the NIH (US) on the Knockout Mouse Project (KOMP). We believe that Mark's background and enthusiasm for the IMPC make him an excellent fit, and we look forward to his taking forward the plans of the IMPC and working with the international community to bring to fruition the goals and ambitions of the consortium.